Clinical Trials
18 trialsNCT03213652 2026-05-27
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04595747 2026-05-22
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05711615 2026-05-15
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02923778 2026-05-13
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06498648 2026-05-13
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT03155620 2026-05-05
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03213704 2026-04-23
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05836571 2026-04-21
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07062003 2025-12-09
Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors, MBRT1 Trial
Mayo Clinic
Phase NA Recruiting
NCT06670976 2025-08-26
Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT06526897 2024-07-30
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Eastern Cooperative Oncology Group
Phase NA Not yet recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04621201 2023-03-29
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Recruiting
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT00004261 2018-02-22
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
University Health Network, Toronto
Phase 1 Terminated
NCT00233948 2015-04-01
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
City of Hope Medical Center
Phase 1/2 Terminated
NCT00562380 2013-07-18
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed